The management of sickle cell nephropathy (SCN) at an early stage is an important issue to prevent renal and cardiovascular morbidity and mortality. This study aimed to evaluate in this population, whether angiotensin converting enzyme inhibitors (ACEIs) treatment could exert a cardio-renal protection in a SCN cohort. Forty-two SCN patients (urine albumin:creatinine ratio (ACR) > 10 mg/mmol) were treated with ACEIs for 6 months, then evaluated for ACR, measured glomerular filtration rate (mGFR) together with haematological and cardiovascular parameters. A 1-month washout was also performed in order to differentiate short-and long-term ACEIs effects. A decrease in ACR baseline value (>30%) was detected in 62% of cases (mean ACR: 46Á4 AE 7Á6 and 26Á4 AE 3Á9 mg/mmol at baseline and 6 months respectively; P = 0Á002), whereas mGFR values were unchanged. ACR decrease was detected at 1 month following ACEI initiation (32Á9 AE 6Á9, P = 0Á02) with a persistent trend after withdrawal (P = 0Á08). ACEIs also decreased diastolic blood pressure (P = 0Á007), pulse wave velocity (P = 0Á01), tricuspid regurgitation velocity (TRV; P = 0Á04), asymmetric dimethyl arginine (ADMA: P = 0Á001) and haemoglobin (P = 0Á01) while conventional haemolytic biomarkers were unchanged. Our data suggest that ACEIs are safe and effective at decreasing albuminuria in sickle cell patients with a beneficial effect on specific mortality risk factors, such as TRV and asymmetric dimethyl arginine.
Summary
The management of sickle cell nephropathy (SCN) at an early stage is an important issue to prevent renal and cardiovascular morbidity and mortality. This study aimed to evaluate in this population, whether angiotensin converting enzyme inhibitors (ACEIs) treatment could exert a cardio-renal protection in a SCN cohort. Forty-two SCN patients (urine albumin:creatinine ratio (ACR) > 10 mg/mmol) were treated with ACEIs for 6 months, then evaluated for ACR, measured glomerular filtration rate (mGFR) together with haematological and cardiovascular parameters. A 1-month washout was also performed in order to differentiate short-and long-term ACEIs effects. A decrease in ACR baseline value (>30%) was detected in 62% of cases (mean ACR: 46Á4 AE 7Á6 and 26Á4 AE 3Á9 mg/mmol at baseline and 6 months respectively; P = 0Á002), whereas mGFR values were unchanged. ACR decrease was detected at 1 month following ACEI initiation (32Á9 AE 6Á9, P = 0Á02) with a persistent trend after withdrawal (P = 0Á08). ACEIs also decreased diastolic blood pressure (P = 0Á007), pulse wave velocity (P = 0Á01), tricuspid regurgitation velocity (TRV; P = 0Á04), asymmetric dimethyl arginine (ADMA: P = 0Á001) and haemoglobin (P = 0Á01) while conventional haemolytic biomarkers were unchanged. Our data suggest that ACEIs are safe and effective at decreasing albuminuria in sickle cell patients with a beneficial effect on specific mortality risk factors, such as TRV and asymmetric dimethyl arginine.
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Sickle cell anaemia-associated nephropathy (SCN) is a growing matter of concern because renal failure affects up to 29% of adult patients with sickle cell anaemia (SCA) (Falk et al, 1992; Powars et al, 2005; Guasch et al, 2006; Asnani & Reid, 2015) and 80% of aging SCA patients (Serjeant et al, 2007) . Thus, early management of SCN at the time of chronic kidney disease (CKD) stage I appears an important issue in order to prevent further glomerular filtration rate (GFR) decrease. Previous works reported the occurrence of SCN very early in childhood, in patients as young as 7 years of age (Dharnidharka et al, 1998) , with microalbuminuria in 26Á5% of cases, increasing to 40% in young adults (Guasch et al, 2006; Haymann et al, 2010) . Macroalbuminuria is reported in 26-40% of SCA patients depending on age and may lead to nephrotic syndrome (Falk et al, 1992) , revealing a focal glomerulosclerosis (Maigne et al, 2010 studied precisely in this population (Saraf et al, 2014) . Indeed, hyperfiltration is a common finding in children and young adults (Schmitt et al, 1998; Barros et al, 2006; Guasch et al, 2006; Haymann et al, 2010; Day et al, 2012) and was shown to be related to chronic haemolysis Day et al, 2012) , whereas the link with albuminuria is still debated (Maier-Redelsperger et al, 2010; Asnani et al, 2011; Day et al, 2012; Hamideh et al, 2014) . The high prevalence of microalbuminuria in SCA patients and the suggested sequence of events leading from micro to macroalbuminuria and, ultimately, chronic renal failure, resemble type 1 diabetic nephropathy history, where glomerular hyperfiltration also occurs at an early stage (Mogensen, 1986) . In accordance with this view, angiotensin-converting enzyme inhibitors (ACEIs) are expected to have a beneficial effect on urine albumin excretion in this population. Consistent with this, three studies have reported the beneficial effects of ACEIs on albuminuria in SCN (Falk et al, 1992; Aoki & Saad, 1995; Foucan et al, 1998) . However, these studies enrolled a very limited number of patients at a late stage of SCN and the potential effect of ACEIs on GFR, haemolytic biomarkers and cardiovascular parameters, which are considered as potential relevant factors for CKD progression, were not studied. The main objective of our study was to evaluate the potential beneficial effect of 6 months ACEIs treatment on albuminuria in adult patients at an early stage of SCN. The second objective was to better understand the influence of the renin angiotensin system on albuminuria and glomerular filtration. In addition, we tested the hypothesis that renin angiotensin activation in SCN may be a key event modulating haemolysis-dependent hyperfiltration and cardiovascular haemodynamics.
Material and methods

Ethics statement
All patients signed written informed consents before inclusion in the study. The R egression de l'Albuminurie dans la N ephropathie Dr epanocytaire (RAND) study design was approved by the local ethics committee (Ref: DGRI CCTIRS MG/CP09.503, 9 July 2009) and registered at ClinicalTrials.-gov (NCT01195818).
Patients and study design
The RAND study is a prospective multicentric non-randomized trial that took place between September 2010 and September 2014. Forty-two adult patients with sickle cell disease were enrolled and evaluated at month 6, as described in Fig 1 . Eligible criteria were adult homozygous SS patients aged >18 years, with a minimum urine albumin:creatinine ratio (ACR) > 10 mg/mmol creatinine on two different random urine spots performed at least 1 month after any acute SCA complication, and a recent estimated GFR (eGFR; Cr EDTA and urinary creatinine clearance were determined during five to six consecutive 30-min clearance periods. GFR measurements were average and standardized for body surface area (1Á73 m 2 ). Hyperfiltration was defined above a threshold value of 110 ml/min/1Á73 m 2 for mGFR in accordance with published data (Maier-Redelsperger et al, 2010) . Renal insufficiency was defined as mGFR < 60 ml/ min/1Á73 m 2 . Estimated GFR (eGFR) was calculated according to the three-variable MDRD formula: 175 9 [creatinine (lmol/l)/88Á9] À 1154 9 [age (years)] À 0203 9 0742 (if female) (Froissart et al, 2005) , but also according to Cockcroft and Gault (Froissart et al, 2005) and CKD Epidemiology Collaboration formulae (Levey et al, 2009 ).
Cardiovascular evaluation
Patients were examined in a quiet, temperature-controlled room. Blood pressure was measured after 15 min of rest in a supine position with an oscillometric method and a cuff-of appropriate size. The average of five consecutive measurements was calculated. Aortic stiffness was measured through the carotid to femoral pulse wave velocity (PWV) between the two sites by the foot-to-foot velocity method (Complior; ALAM Medical, Pantin, France), as described and validated . PWV expresses the elastic properties of the descending and abdominal aorta and the iliofemoral segments, and is reported as the mean of four determinations. Doppler echocardiography examinations were performed by an experienced physician according to recent guidelines (Lang et al, 2015) . All examinations were analysed off-line, blinded to study time point, clinical and biological data. Left ventricular mass was derived and indexed to body surface area (Lang et al, 2015) . LV ejection fraction (LVEF) was derived from 2D mode using Simpson's modified biplane method. From pulsed wave Doppler mode, cardiac output was calculated and indexed to body surface area as recommended (Quiñones et al, 2002; Nagueh et al, 2009) . From continuous wave Doppler, peak tricuspid regurgitation was recorded in multiple views and the highest level of velocity was selected. Elevated pulmonary systolic pressure was defined by a peak tricuspid regurgitation velocity (TRV) > 2Á5 m/s (Klings et al, 2014) .
Assays
Serum and urinary creatinine levels and uric acid levels were measured by a Konelab 20 analyser (Thermo Fisher Scientific, Vantaa, Finland). Total CO 2 in blood, ionized calcium, sodium, and potassium levels were measured with an ABL 815 blood gas analyse (Radiometer, Bronshoj, Denmark). Calcium and magnesium serum and urinary levels were measured with a 3300 atomic absorption spectrometer (PerkinElmer, Shelton, CT, USA). Plasma aldosterone was measured by radioimmunoassay kits (Immunodiagnostics Systems Ltd., Paris, France) Plasma asymmetric dimethyl arginine (ADMA), symmetric dimethyl arginine (SDMA) and arginin were measured by high liquid performance chromatography coupled with fluorimeter detection. Other laboratory values were measured using standard hospital laboratory techniques.
Statistical analyses
The sample size was estimated to a minimum of 42 patients in order to show a difference >30% ACR decrease from baseline value with a power of 0Á9, an alpha level of 0Á01 and a 
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Results
Effect of ACEIs on albuminuria
Fifty-one patients were preselected according to the presence of albuminuria and a presumed hyperfiltration based upon a recent eGFR value. Forty-two patients were evaluable for statistical analysis as nine patients were excluded (eight patients between baseline and V2 and one between V2 and V3; Fig 1) : six refused the 6-months evaluation (V3) and withdrew their consent (two patients stopped ACEIs due to vertigo and refused the switch to irbesartan, four patients interrupted treatment, though no side effect was reported) and three patients had an ACR below 3 mg/mmol at inclusion (despite an ACR > 10 mg/mmol in two previous random urine samples, performed at least 1 month after any sickle cell-related events). Overall, 25 females and 17 males were included with a median age of 29Á0 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] years and a median body mass index of 21Á6 [20Á4-23Á2] kg/m 2 . A history of SCA complications, such as leg ulcer, retinopathy, acute chest syndrome, osteonecrosis and strokes was detected in 8Á9%, 29%, 75%, 20% and 2% of cases respectively. Thirty-five per cent of SCA male patients experienced at least one priapism crisis. At baseline, 24 patients were microalbuminuric (ACR 3-30 mg/mmol in a 24-h urine collection) and 18 patients were macroalbuminuric. The median interval between V1 and V3 was 183 days . ACEIs treatment for 6 months was effective at decreasing albuminuria, from a mean of 46Á4 AE 7Á6 at inclusion to 26Á4 AE 3Á9 mg/mmol after 6 months (P = 0Á002), with an ACR decrease >30% of basal value in 62% of cases (n = 26/42) ( Table I, Fig 2) . This decrease occurred as early as 1 month following ACEI initiation for most patients (mean ACR: 32Á9 AE 6Á9 mg/mmol, P = 0Á007), with a persistent trend after the 1-month washout (28Á1 AE 3Á5 mg/mmol, P = 0.08). Of note, macroalbuminuric patients experienced a dramatic ACR decrease from a mean value of 87Á6 AE 12Á2 to 38Á7 AE 7Á1 mg/mmol between 0 and 6 months respectively (P = 0Á001), with a persistent effect (37Á3 AE 5Á7 mg/mmol) after a 1-month washout (P = 0Á001). Overall, ACR decreased in 83% of macroalbuminuric patients (n = 15/18) with 50% of patients (n = 9/18) classified as microalbuminuric at 6 months. Conversely, no significant effect on albuminuria was detected in the microalbuminuric group (Fig 2) : ACR increased in 37% of cases (n = 9/24) at 6 months [with the onset of macroalbuminuria in 21% of patients (n = 5/ 24)] and decreased above 30% of baseline in 46% (n = 11/ 24) of cases, without noticeable change 1 month after ACEI withdrawal.
Of note, 19/42 patients were under long-term hydroxycarbamide treatment (mean treatment duration of 6 years), with no reported change in dosage during our study. No difference in albuminuria was detected between patients treated with and without hydroxycarbamide at inclusion or month 6.
Effect of ACEIs on renal function
Renal function, assessed by mGFR and eGFR, did not change between baseline and month 6 ( Table I) . As expected, eGFR values were rather good estimates of measured creatinine clearance but overestimated plasma or renal mGFR by 20-40%. Surprisingly, albuminuria was positively associated with mGFR at month 6 of ACEI treatment but not at baseline (Fig 3A,B) .
Cardio-vascular effects of ACEIs
Doppler echocardiography was performed both at baseline and after 6 months in 86% of patients and pulmonary pressure evaluation was feasible at both study time-points in 62% of cases. TRV decreased significantly between baseline and month 6 (mean value 2Á49 AE 0Á03 vs. 2Á42 AE 0Á03 m/s respectively; Table II ). Of note, among the 11 patients with a high TRV value (above 2Á5 m/s) at baseline, nine patients showed decreased TRV under treatment, one increased and one remained stable (mean TRV value decreased from 2Á66 to 2Á52 m/s in this subgroup) (Fig 3) . Surprisingly, albuminuria was positively associated with TRV values both at baseline and after six months ACEIs treatment (Fig 3C,D) . Cardiac output, LVDF and LV mass index, were unchanged between baseline and month 6 while diastolic and mean blood pressure and also aortic PWV significantly decreased (Table II) .
Biological effects of ACEIs
No difference in kalaemia was detected between baseline and month 6 (Table III) . Conversely, haemoglobin decreased from 83 to 78 g/l (P = 0Á01), with no change in erythropoietin level. Whereas conventional haemolytic biomarkers, such as reticulocyte count, bilirubin or lactate dehydrogenase (LDH) levels were unchanged, ADMA decreased significantly at month 6.
Side effects
During the whole study, patients were hospitalized for vasoocclusive crisis (VOC, n = 2), acute chest syndrome (ACS, n = 2), pneumonia (n = 1) and gastroenteritis (n = 1), with no reported ACEI treatment interruption. No treatment was discontinued for a reported hyperkalaemia or orthostatic hypotension. One patient was switched to irbesartan due to persistent cough and thus remained in the analysis.
Discussion
This is the largest prospective study of SCN to date, which aimed to evaluate the effect of 6 months ACEI treatment on albuminuria in SCA patients and also to test a potential effect after ACEI withdrawal. It is the first study conducted in SCA patients at an early stage of glomerulopathy, i.e. CKD stage I, with most patients with hyperfiltration assessed by mGFR. This study was also designed to evaluate the renin angiotensin system activation on renal, cardiovascular and biological parameters in SCN patients. Our results indeed show a beneficial effect, with a significant decrease of albuminuria following 6 months ACEI treatment (primary endpoint). These data are in agreement with one previous report showing a reduced proteinuria following a 2-week enalapril treatment in a series of 10 macroalbuminuric patients (Falk et al, 1992) . A recent phase II trial of losartan given for 6 months also showed an ACR decrease of more than 25% of baseline in 5/6 macroalbuminuric patients and 7/12 microalbuminuric patients (Quinn et al, 2017) . Although our study was primarily designed to evaluate the whole population of SCA patients with an ACR ratio above 10 mg/mmol, we found that ACEI were very effective on macroalbuminuria, with, surprisingly, no significant effect on microalbuminuria, in contrast to previous series (Foucan et al, 1998; Quinn et al, 2017 ). The different populations tested probably explain this discrepancy: in our series, patients were selected at an early stage of SCN (assessed by hyperfiltration status), thus presumably when intrarenal renin angiotensin activation may not be the general rule, especially at the time of microalbuminuria. Conversely, an ACR decrease of more than 30% of baseline in most macroalbuminuric patients (and 46% of microalbuminuric patients) suggests a renin angiotensin-mediated glomerular pressure increase, responsive to ACEIs presumably through efferent arteriolar Comparison of the albumin:creatinine ratio (ACR) between baseline and the different visits for the whole population and the two macroalbuminuric (n = 18) and microalbuminuric subgroups (n = 24). *P < 0Á05; **P < 0Á001.
vasodilation (Mathiesen et al, 1991; Anderson et al, 1993) . The occurrence of reduced albuminuria as early as 1 month following treatment initiation is in accordance with this renal haemodynamic effect; however, long term glomerular structural changes are probably also occurring because a sustained reduced albuminuria was still detected 1 month after ACEIs withdrawal (as shown in macroalbuminuric patients). Therefore, as no predictors of ACR changes were found (data not shown), our data indicate that ACEIs treatment challenge should be performed in albuminuric SCA patients for at least 1 month, when the ACR should be checked. Persistent albuminuria in 84Á6% of patients (ACR > 3 mg/mmol) may be (Maigne et al, 2010) , but also to stretched filtration slits related to enlarged glomeruli, which are a striking feature in this population (Guasch et al, 1997; Saborio & Scheinman, 1999) . Glomerulomegaly may also account for hyperfiltration through an increased filtration surface and thus would explain the tight links detected between albuminuria and GFR unmasked by ACEIs treatment (see Fig 3B) . In our population, although cardiac output was high and systemic blood pressure and aortic stiffness were low compared to general population (Reference Values for Arterial Stiffness' Collaboration, 2010), cardiac output was unchanged under ACEIs, whereas a significant decrease on diastolic blood pressure and PWV was detected. This decrease in arterial resistance under treatment also affected the TRV, which is a well-known mortality risk factor in this population (Gladwin et al, 2004) . In this respect, we believe that a significant, even mild, TRV improvement within a 6-month period is of clinical relevance, although this needs to be confirmed by a longer follow-up.
Angiotensin converting enzyme inhibitors treatment was well tolerated with only very few patients requiring hospitalization for vaso-occlusive crisis or ACS during the study. Moreover, despite a low basal systemic blood pressure, and a significant ACEI decrease of diastolic and mean blood pressure, no symptomatic hypotension was recorded but three individuals did interrupt the treatment for vertigo, with one successfully switched to angiotensin II receptor blockers; two who refused the switch. One concern prior to the initiation of the study was a potential ACEI-mediated worsening of pre-existing anaemia (Ajmal et al, 2013) . As a matter of fact, haemoglobin level decrease was significant but mild in all patients, with no reported clinical symptoms or events. The mechanism at play is a matter of controversy as several studies showed that ACEIs might inhibit erythropoietin production while others demonstrated that angiotensin II blockers inhibited early erythroid progenitors proliferation (Mrug et al, 1997) . In our population, we favour a mild inhibition of erythropoiesis as no decrease in erythropoietin was detected following 6 months of ACEI treatment. Conventional haemolytic biomarkers, such as reticulocyte count, LDH and bilirubin remained unchanged, whereas ADMA concentration decrease was highly significant. Indeed, high plasma ADMA levels were previously reported in SCA patients (Schnog et al, 2005; Landburg et al, 2008) and related to proteolysis following haemolytic stress in sickle red blood cells (D'Alecy & Billecke, 2010) . In accordance to the general view that ADMA inhibits nitric oxide synthase activity leading to increased arteriolar tone and, ultimately, endothelial dysfunction (Kielstein et al, 2004) , a relevant link between high ADMA concentration and SCA haemolytic phenotype (noteworthy pulmonary hypertension) has been reported by several authors (Landburg et al, 2010; El-Shanshory et al, 2013) . ADMA decrease under ACEI medication would thus be a key event contributing to endothelial function improvement through an increased nitric oxide bioavailability. Indeed, previous studies reported that endothelial function improvement in diabetic nephropathy under ACEIs was also related to proteinuria and ADMA decrease (Maas, 2005) . In our population, ACEI treatment decreased albuminuria, TRV and ADMA, thus suggesting that the renin angiotensin system probably has a pivotal role on morbidity and mortality in SCA patients, either directly and/or through ADMA interaction. The mechanisms responsible for ADMA decrease under ACEI treatment are probably multifactorial (Maas, 2005) and beyond the scope of the present study. The design of the present study was based on a prospective intention-to-treat trial with a 1-month washout period after 6 months treatment in order to differentiate short and long term ACEI effects on albuminuria and cardiovascular parameters, but also glomerular filtration (Sochett et al, 2006) . Our study suffers some limitations due to patient compliance, as suggested by the absence of aldosterone decrease (and renin increase) detected in few patients, though plasma renin and aldosterone were significantly different before and under ACEI treatment in the whole population. Moreover, despite a careful evaluation before inclusion, three patients selected on the presence of at least two previous urine samples with an ACR > 10 mg/mmol had no detected albuminuria at the time of ACEI initiation (and thus were excluded), thus raising the issue that 24-h urine collections would be more accurate than random urine samples to assess albuminuria in SCA patients, as previously suggested (Lima et al, 2002; Asnani & Reid, 2013) . The lack of reported albuminuria decrease within the microalbuminuric subgroup does not rule out a potential beneficial effect because the study was not initially designed to analyse subgroups (a regression to the mean phenomenon could have impacted subgroup analysis results). Finally, 6 months of treatment with ACEIs may appear a short time schedule and does not preclude longer-term cardio-renal effects. In our view, another study addressing the effect of ACEIs at later stages of SCN, especially in chronic renal failure, is urgently required.
Despite the limitations mentioned above, our data strongly suggest that, among patients with early stage SCN, treatment with ACEIs appears safe and effective in decreasing both albuminuria (despite no effect on cardiac output and hyperfiltration status), and other well-known strong predictors of mortality in this population, such as TRV (Gladwin et al, 2004) , while improving nitric oxide bioavailability through ADMA decrease.
